諾輝健康-B(06606.HK)年度收入總額預增190.8%至207.8% 毛利率呈上升趨勢
格隆匯1月14日丨諾輝健康-B(06606.HK)發佈公吿,集團截至2021年12月31日止年度的收入總額預期將介乎人民幣2.052億元至2.172億元之間,同比增長190.8%至207.8%。集團該年度的毛利預期將介乎人民幣1.47億元至1.58億元之間,同比增長294.6%至324.2%。收入總額及毛利增加主要是因為集團的產品(即常衞清及噗噗管)的收入及毛利增加,從而使得收入總額大幅增加。
此外,公司該年度的毛利率預期將介乎67.7%至77.0%之間,較上年度的約52.8%呈上升趨勢。集團的整體毛利率提高主要是因為常衞清及噗噗管的毛利率有所增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.